Back to BAKER BROS. ADVISORS LP BAKER BROS. ADVISORS LP

CLDXCLDX
Showing 8 of 11 quarters

Position history for BAKER BROS. ADVISORS LPBAKER BROS. ADVISORS LP's holdings in CELLDEX THERAPEUTICS INC NEW

BAKER BROS. ADVISORS LP holds 1.2M shares of CLDX (CELLDEX THERAPEUTICS INC NEW), worth $44M as of 2026-Q2. The position was increased (+77.7% shares). CLDX represents 0.2% of BAKER BROS. ADVISORS LP's portfolio.

Current Value

$44M

Current Shares

1.2M

Total Value Change

+$35.6M

Total Shares Change

+934,967

Quarter-by-Quarter History
QuarterActionSharesChangeValueWeightPriceConviction
2026-Q2
Latest
Increased
1.2M
+77.7%
$44M0.2%$37.21
53
2026-Q1
Unchanged
665,370
0.0%
$21.1M0.1%$31.72
0
2025-Q4
Unchanged
665,370
0.0%
$18.1M0.1%$27.16
0
2025-Q3
Unchanged
665,370
0.0%
$17.2M0.1%$25.87
0
2025-Q2
Increased
665,370
+168.7%
$13.5M0.1%$20.35
54
2025-Q1
Unchanged
247,644
0.0%
$4.5M0.0%$18.15
0
2024-Q4
Unchanged
247,644
0.0%
$6.3M0.1%$25.27
0
2024-Q3
Unchanged
247,644
0.0%
$8.4M0.1%$33.99
0

Other major holders of CLDX: BNP PARIBAS FINANCIAL MARKETS, FMR LLC, WELLINGTON MANAGEMENT GROUP LLP

Analytics tracking helps us improve the product. Essential functions stay on either way. How analytics data is used